November 4th 2024
The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.
Dr. Sutherland discusses what's on the horizon in tibial nerve stimulation
March 26th 2024“I think the long and short of it is we know tibial nerve stimulation works, we're just trying to identify what's the best way by which we can deliver it conveniently and cost effectively to the patient,” says Suzette E. Sutherland, MD, MS, FPMRS.
Dr. Werneburg on machine learning and AI’s potential in urology
March 13th 2024"We're really enthusiastic on the overactive bladder end and on the antibiotic resistance end, but much more broadly, [AI is] set up to help us counsel our patients better and help us to improve outcomes for our patients as well," says Glenn T. Werneburg, MD, PhD.
Dr. Tabakin on providing accurate information on third-line OAB treatments
March 4th 2024"I would say that the biggest take-home is that many of our patients are using social media for their health care information, and this may influence their preferences [and] their decision-making," says Alexandra Tabakin, MD.
Navigating Safety Concerns and Adverse Effects in OAB Medications
February 8th 2024In this episode, experts review safety concerns, drug interactions, and common adverse effects (AEs) associated with overactive bladder (OAB) medications. They discuss the impact of AEs like constipation, hypertension, and dry mouth on patient quality of life, strategies for managing these effects, and circumstances warranting a change in treatment. The experts also examine recent clinical evidence linking anti-cholinergic treatments to an increased risk of dementia in older patients, discussing its implications for clinical practice and strategies for urologists to remain vigilant about such safety concerns.
Selection Preferences in Second-Line Therapy Classes for OAB
February 1st 2024Experts explore the clinical benefits and limitations of standard pharmacological options, like anti-muscarinic agents and beta-3 adrenergic agonists, and share their preferences and experiences in selecting and managing treatments for OAB, focusing on the effectiveness and patient-specific considerations in their clinical practice. In this episode, Dr. Kennelly, alongside Drs. Eilber and Benson, discusses the transition to second-line therapies for overactive bladder, focusing on medication classes like anticholinergics and beta-3 agonists. They explore patient-centered considerations such as medication compliance, cost, insurance coverage, and the chronic nature of overactive bladder management, emphasizing individualized treatment based on patient needs and health profiles.
Patient Assessment and Impact of OAB on Patients’ Quality of Life
February 1st 2024Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber delve into the significant impact of OAB on patients' quality of life, including its effects on daily activities and mental well-being, and how this burden shapes clinical decisions in the early stages of treatment and selection of appropriate therapeutic options.
Expert: Online resources help improve incontinence, do not reduce clinic visits
January 14th 2024"What we found was that the primary outcome didn't change. Whether you had access to eADVICE or you didn't, most people still wanted to see the specialist at the end of their time, including people who were already dry," says Patrina H. Y. Caldwell, BMed, FRACP, PhD.